Istari Oncology Overview
- Year Founded
-
2016
- Status
-
Out of Business
- Employees
-
8
- Latest Deal Type
-
Out of Business
- Investors
-
1
Istari Oncology General Information
Description
Operator of a biotechnology company intended to offer treatment of glioblastoma and a wide variety of tumors. The company's platform delivers vaccines by direct intratumoral delivery via convection-enhanced delivery, which bypasses the blood-brain barrier and reduces systemic toxicity, and its software permits accurate and reproducible drug distribution and injection accuracy, enabling doctors to treat tumors.
Contact Information
Website
www.istarioncology.comCorporate Office
- 6 Davis Drive
- Suite 155
- Durham, NC 27709
- United States
Corporate Office
- 6 Davis Drive
- Suite 155
- Durham, NC 27709
- United States
Istari Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 04-Jul-2026 | Completed | Out of Business | |||
| 5. Later Stage VC (Series B) | 19-Apr-2021 | Completed | Clinical Trials - Phase 2 | |||
| 4. Early Stage VC (Series A) | 29-Jul-2020 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC | 25-May-2017 | Completed | Clinical Trials - General | |||
| 2. Seed Round | 13-Feb-2017 | $4M | $4M | Completed | Clinical Trials - General | |
| 1. University Spin-Out | 01-Jan-2016 | Completed | Startup |
Istari Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Istari Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Istari Oncology Patents
Istari Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025019822-A1 | Methods of treatment with a chimeric poliovirus in patients with glioblastoma | Inactive | 19-Jul-2023 | ||
| WO-2023141236-A2 | Methods for treating bladder cancers by intravesical instillation of a chimeric poliovirus | Inactive | 19-Jan-2022 | ||
| WO-2023141236-A3 | Methods for treating bladder cancers by intravesical instillation of a chimeric poliovirus | Inactive | 19-Jan-2022 | ||
| EP-4466000-A2 | Oncolytic virus regimens for the treatment of cancer | Inactive | 19-Jan-2022 | ||
| US-20250009823-A1 | Oncolytic virus regimens for the treatment of cancer | Pending | 19-Jan-2022 | A61K35/768 |
Istari Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Istari Oncology Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Duke University | University |
Istari Oncology FAQs
-
When was Istari Oncology founded?
Istari Oncology was founded in 2016.
-
Where is Istari Oncology headquartered?
Istari Oncology is headquartered in Durham, NC.
-
What is the size of Istari Oncology?
Istari Oncology has 8 total employees.
-
What industry is Istari Oncology in?
Istari Oncology’s primary industry is Drug Discovery.
-
Is Istari Oncology a private or public company?
Istari Oncology is a Private company.
-
What is Istari Oncology’s current revenue?
The current revenue for Istari Oncology is .
-
How much funding has Istari Oncology raised over time?
Istari Oncology has raised $63.6M.
-
Who are Istari Oncology’s investors?
Duke University has invested in Istari Oncology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
